Home » Stocks » NeoGenomics

NeoGenomics, Inc. (NEO)

Stock Price: $41.34 USD -1.12 (-2.64%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $42.00 +0.66 (1.60%) Oct 23, 4:42 PM

Stock Price Chart

Key Info

Market Cap 4.57B
Revenue (ttm) 404.55M
Net Income (ttm) -5.36M
Shares Out 110.43M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE 121.95
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $41.34
Previous Close $42.46
Change ($) -1.12
Change (%) -2.64%
Day's Open 42.47
Day's Range 40.65 - 43.50
Day's Volume 616,102
52-Week Range 19.43 - 44.58

More Stats

Market Cap 4.57B
Enterprise Value 4.49B
Earnings Date (est) Oct 27, 2020
Ex-Dividend Date n/a
Shares Outstanding 110.43M
Float 105.69M
EPS (basic) -0.05
EPS (diluted) -0.05
FCF / Share -0.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.00M
Short Ratio 5.56
Short % of Float 3.79%
Beta 0.80
PE Ratio n/a
Forward PE 121.95
P/FCF Ratio n/a
PS Ratio 11.28
PB Ratio 7.42
Revenue 404.55M
Operating Income -18.22M
Net Income -5.36M
Free Cash Flow -6.18M
Net Cash 75.35M
Net Cash / Share 0.68
Gross Margin 48.66%
Operating Margin -4.50%
Profit Margin -1.30%
FCF Margin -1.53%
ROA -1.04%
ROE -0.94%
ROIC -4.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(3.07% upside)
Current: $41.34
Target: 42.61
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth47.73%15.19%3.64%132.27%14.62%31%11.02%37.68%26.51%-
Gross Profit19712710298.1043.7640.7131.7426.8419.4315.78
Operating Income13.0110.043.962.16-5.642.223.171.21-0.41-2.96
Net Income8.012.64-0.40-6.14-2.541.132.030.07-1.18-3.30
Shares Outstanding10085.6279.4377.5460.5353.4848.2645.0342.7637.33
Earnings Per Share0.080.07-0.14-0.40-
EPS Growth14.29%-----50%----
Operating Cash Flow23.3744.7918.0421.486.399.452.23-0.490.07-2.05
Capital Expenditures-20.03-14.31-13.69-7.54-2.22-3.77-2.01-2.62-0.90-0.92
Free Cash Flow3.3430.484.3513.944.185.680.22-3.11-0.83-2.97
Cash & Equivalents1739.8112.8212.5323.4233.694.831.873.131.60
Total Debt13311210510671.388.4810.3613.778.616.79
Net Cash / Debt40.14-102-92.60-93.64-47.9625.21-5.53-11.90-5.49-5.19
Book Value50732017216421060.4121.719.225.903.14
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NeoGenomics, Inc.
Country United States
Employees 1,700
CEO Douglas M. Van Oort

Stock Information

Ticker Symbol NEO
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: NEO
IPO Date November 2, 1999


NeoGenomics operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.